Examination of the Biomark Assay as an Alternative to Oncotype DX for Defining Chemotherapy Benefit

Oncology Letters - Greece
doi 10.3892/ol.2018.9784
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Spandidos Publications

Related search

Oncotype DX Breast Cancer Recurrence Score Resists Inter-Assay Reproducibility With RT2-Profiler Multiplex RT-PCR

Scientific Reports
Multidisciplinary
2019English

Racial Variation in the Uptake of Oncotype DX Testing for Early-Stage Breast Cancer

Journal of Clinical Oncology
Cancer ResearchMedicineOncology
2016English

Community Clinical Practice Patterns and Mortality in Patients With Intermediate Oncotype DX Recurrence Scores: Who Benefits From Chemotherapy?

Cancer
Cancer ResearchOncology
2018English

The Impact of Oncotype DX® Recurrence Score of Paraffin-Embedded Core Biopsy Tissues in Predicting Response to Neoadjuvant Chemotherapy in Women With Breast Cancer

Breast Disease
MedicineCancer ResearchOncology
2016English

Evaluation of the Affymetrix CytoScan®Dx Assay for Developmental Delay

Expert Review of Molecular Diagnostics
Forensic MedicineGeneticsPathologyMolecular MedicineMolecular Biology
2014English

Oncotype Dx® in the Sistema Único De Saúde Do Brasil (Sus): Result of 125 Cases

2019English

Oncotype Dx Recurrence Score Among BRCA1/2 Germline Mutation Carriers With Hormone Receptors Positive Breast Cancer

International Journal of Cancer
Cancer ResearchOncology
2017English

ERCC1 as a Biomarker for Bladder Cancer Patients Likely to Benefit From Adjuvant Chemotherapy

BMC Cancer
Cancer ResearchOncologyGenetics
2012English

Dna Isolation From Human Urine Stain as an Alternative Material for Personal Identification Examination

Folia Medica Indonesiana
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy